-transparent.png){kind=logo}
Basic research in Epstein-Barr virus (EBV) molecular genetics has provided means to maintain episomes in human cells, to efficiently deliver episomes with up to 150 kbp of heterologous DNA to human B lymphocytes, and to immortalize human B lymphocytes with EBV recombinants that can maintain up to 120 kbp of heterologous DNA. Episome maintenance requires an EBV nuclear protein, EBNA1, whereas immortalization of cells with EBV recombinants requires EBNA1, EBNA2, EBNA3A, EBNA3C, EBNALP, and LMP1. EBV-derived vectors are useful for experimental genetic reconstitution in B lymphocytes, a cell type frequently used in establishing repositories of human genetic deficiencies. The ability of EBV-infected cells to establish a balanced state of persistence in normal humans raises the possibility that cells infected with EBV recombinants could be useful for genetic reconstitution, in vivo.
E S Robertson, and
T Ooka, and
E D Kieff
January 2000,
Advances in virus research,
E S Robertson, and
T Ooka, and
E D Kieff
October 1998,
Current opinion in biotechnology,
E S Robertson, and
T Ooka, and
E D Kieff
January 2002,
Methods in enzymology,
E S Robertson, and
T Ooka, and
E D Kieff
May 2003,
Human gene therapy,
E S Robertson, and
T Ooka, and
E D Kieff
May 1998,
Human gene therapy,
E S Robertson, and
T Ooka, and
E D Kieff
June 1998,
Leukemia & lymphoma,
E S Robertson, and
T Ooka, and
E D Kieff
May 1989,
Virology,
E S Robertson, and
T Ooka, and
E D Kieff
May 1998,
Human gene therapy,
E S Robertson, and
T Ooka, and
E D Kieff
April 1990,
Blood,
E S Robertson, and
T Ooka, and
E D Kieff
January 1992,
Methods in molecular biology (Clifton, N.J.),
